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Summary: We report a preliminary evaluation of an immunoinhibition assay for creatine kinase isoform quantifi-
cation. The procedure employs the monoclonal antibody CKM-G01, which inhibits the native M subunit of creatine
kinase. The antibody does not inhibit the M subunit modified by removal of lysine by plasma carboxypeptidase N.
Residual activity after treatment with the antibody is therefore due to serum delysinated isoforms. The ratio in-
hibited/residual activity correlated directly with the ratio tissue/serum isoforms. Analysis of the total imprecision
of isoform ratio measurement gave a coefFicient of Variation between 5.9 and 21.1%. Reference intervals for the
ratio were 0.14-0.79 in females and 0.19-0.95 in men (p = 0.0046). Analytical and clinical comparison with
alternative isoform procedures gave good results, showing that this assay can be used äs alternative to the widely
accepted electrophoretic method for measurement of the creatine kinase isoform ratio.
Introduction
High resolution Separation techniques have shown the
presence of multiple forms of creatine kinase (ATP: cre-
atine N-phosphotransferase, EC 2.7.3.2) isoenzyines in
human serum (for review see L c. (1)). It has been well
documented that there are at least three creatine kinase
MM isoforms (subforms derived from the same iso-
enzyme that exhibit the same specific catalytic activity
and slightly differerit isoelectric points), denoted äs
MM1, MM2, and MM3, and two creatine kinase MB
isoforms, denoted äs MB l and MB2 (2). Only MM3 and
MB2 (the gene-encpded forms) are present in extracts
of muscle tissue, whereas MM2, MMl,.arid MB l re-
present the additiönal forms produced post-trans-
lationally by hydrolytic removal of the carboxyrterminal
lysine residue on the native M subunit by plasma carb-
oxypeptidase N (3).
The clinical Utility of creatine kinase isoform determi-
nation has been actively investigated (l, 2, 4). Determi-
nation of the isoforms in the serum of patients with
acute myocardial infarction prövides an early detection
of acute enzyme release firom necrotic myocardium (5,
6) and distinguishes between reperfused and non-reper-
fused patients after thrombolytic therapy (7—9). In par-
ticular, the ratio of the tissue isoforms (i. e., the gene
products) to the serum isoforms is diagnostically more
sensitive than the concentrations of individual isoforms
(l, 2). However, due to technical limitations of current
analytical methods, determination of the isoform ratio
appears to be too cumbersome and slow for therapeutic
and management decision making (10). Indeed, a
simple, rapid, and automated method for measuring cre-
atine kinase isoforms suitable for routine analysis, is still
lacking (11). Significant improvement would be ex-
pected with immunpassay methods. Two diagnostic re-
agents, using isoform-specific monoclonal antibodies,
were recently introduced (12, 13). However, one pro-
cedure determines only the MM1 isoform, whereas the
examination of the performance of the antibodies used
in the latter demonstrated significant cross-reaction with
different isoforms (14).
In 1990, Suzuki et al, (15) described a monoclonal anti-
body (CKM-G01) that inhibited > 99% of the activity
of human creatine kinase purified from muscle but ap-
proximately 55% of creatine kinase activity in serum.
Chromatofocusing analysis revealed that CKM-G01
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specifically inhibited only the original creatine kinase
M-subunil and not the subunit modified by removal of
carboxy-terminal lysine by serum carboxypeptidase
(15). Using CKM-G01, an immunoinhibition method
was devised by latron Laboratories (Tokyo, Japan).
Since the antibody inhibited MM3 completely, approxi-
mately 50% of MM2 and MB2, and does not inhibit
MM l and MB l activities, it was possible to calculate
an "Inhibition index" expressing the ratio of the tissue
isoforms with lysine on the M monomer, to the serum
isoforms with no lysine at carboxy terminus of the M
monomer. Notwithstanding two preliminary studies pub-
lished s "Abstracts" by the latron research group (16,
17), we report here the first comprehensive evaluation of
this automated assay since its commercialization, with a
wider documentation of its analytical performance and
a preliminary study on its clinical value for the differen-
tiation of acute myocardial infarction patients with suc-




Total creatine kinase activity was determined by a coupled reaction
of glucokinase and glucose-6-phosphate dehydrogenase (18), using
a diagnostic kit (latro-CK; latron Laboratories Inc.). Two reagents
were used: reagent A was 75 mmol/1 imidazole acetate buffer (pH
6.7) containing, per litre, 1.8 mmol adenosine 5'-diphosphate, 2.5
mmol nicotinamide adenine dinucleotide phosphate, 25 mmol glu-
cose, 25 mmol N-acetylcysteine, 2.4 mmol ethylenediaminetetra-
acetic acid, 12 μιηοΐ diadenosine pentaphosphate, 5 mmol adenos-
ine 5'-monophosphate, 4000 U glucokinase and 1300 U glucose-6-
phosphate dehydrogenase. Reagent B was 25 mmol/1 Tris buffer
(pH 7.5) containing, per litre, 130 mmol creatine phosphate and 50
mmol magnesium acetate. We applied this method to the Cobas
Bio analyser (Hoffman-La R che, Basle, Switzerland). After the
sample (4 μΐ, diluent volume 30 μΐ) had been incubated with 130
μΐ of reagent A for 3 minutes at 37 °C, the reaction was started by
addition of 20 μΐ of reagent B. The increase in absorbance of re-
duced nicotinamide adenine dinucleotide phosphate at 340 nm was
monitored for the sample vs the reagent blank for 150 seconds,
after a 60-second lag phase. Creatine kinase activity was expressed
s U/l (micromoles of Substrate converted per minute per litre). For
the comparison studies, total creatine kinase activity was measured
at 37 °C by the method recommended by the International Feder-
ation of Ciinical Chemistry, with reagents frorn Boehringer,
Mannheim, Germany.
The immunoinhibition assay was done by the method for creatine
kinase described above, except that l mg/1 of the monocl nal anti-
body CKM-G01, obtained from latron, was-added to reagent A. A
creatine kinase isoform ratio was calculated from total and residual
(not-inhibited) activities s follows: total creatine kinase — residual
creatine kinase/residuai creatine kinase.
Two creatine kinase isofonn procedures were utilized for the com-
parison studies. Complete creatine kinase MM and MB isoform
patterns were separated by electrophoresis (1400 V for 16 minutes)
on agarose gel with the automated Rapid Electrophoresis Analyser/
Electronic Data Center - REP/EDC™ System (Helena Labora-
tories, Beaumont, TX 77704, USA). After electrophoresis, the gel
was treated with the creatine kinase Substrate reagent (REP CK
Isoforms Reagent, Helena Laboratories) at 45 °C, then dried for 5
minutes at 54 °C. Isoforms were detected by fluorescenee densitOr
metry. Specimens with total creatine kinase activity exceeding
1000 U/l were diluted before analysis. Additionally, the creatine
kinase MM1 isoform, i,e. the serum-specific isoform, was deter-
mined by an immunochemical procedure s previously described
(12). Since the MM l isoform is the principal component of non-
inhibited activity in the evaluated assay (see above), the results of
the latter method were directly compared with the remaining cre-
atine kinase activity after Inhibition with CKM-G01 antibody.
Creatine kinase MB mass concentrations were determined with the
Magic Lite CK-MB assay (Ciba Corning Diagnostics Corp., E.
Walpole, MA 02032, USA), which uses a double-antibody chemi-
luminescent procedure. Technical details, imprecision, and refer-
ence r nge for healthy individuals, 0-6 μg/l, have been published
previously (19). Myoglobin was determined with the Behringwerke
immunonephelometric reagents (NA Latex Myoglobin Test,
Behringwerke, Marburg, Germ ny) consisting of shell and core
particles coated with anti-myoglobia antibodies and adapted to the
selective multipfotein Behring Nephelometer Analyser (20). The
previously established upper reference limit was 45 μ^/1 (20).
The purified human creatine kinase isoforms, employed for speci-
ficity and recovery studies, were obtained from Calbiochem Corp.
(La Jolla, CA 92037, USA) (MM3 isofbrrn) and from Aalto Scien-
tific (Vista, CA 92083, USA) (MM1 isofprm). The composition
of these commercially available materials was assayed by isoform
electrophoresis (see above) and the homogeneity of each prep^·
aration was confirmed.
Blood samples
We studied ten patients (eight men and two women, aged 41 to 70
years) who were admitted because of acute myocardial infarctioa
to the Department of Anaesthesia and Reanimation pf our hospitai,
and had undergone intravenous thrombolytic therapy 177 minutes
(average; r nge 90-240) after the onset of ehest pain. The reestab-
lishment of anterograde flow in the occluded coronary artery was
assessed non-invasively by clinical, electrocardiographic, and bio-
chemic l criteri (e. g. persistence pf ehest pain and of electrocar^
diographic changes, absence of reperfusion arrhythmias, analysis
of creatine kinase MB and myoglobin release rates) (21-23). On
the basis of these criteri , five patients were successfully com-
pletely reperfused and five patients not. Peripheral venous blood
samples were obtained at the time of thrombolytic therapy and
approximately 2, 4 and 6 hours thereafter. Sampling time was re-
lated to the time of thrombolysis. Samples for isoform analysis
were treated with ethylenediaminetetraacetic acid to give a final
concentration of 5 mmol/1, then stored at -20 °C (1). Serum
samples were assayed immediately for total creatine kinase, cre-
atine kinase MB, and myoglobin; isoform assays were performed
within 24 hours after collection, without delay after thawing the
samples.
In addition, 128 non^hospitalized apparently healthy subjects (80
women and 48 men, whose ages rariged from 20 to.70 years), -with
normal results for serum biochemical and haematological tests and
without clinical evidence of cardiac and muscle diseases, were
studied to establish the reference i terval fpr creatine kinase iso-
forms in serum by the evaluated method.
Results
Specificity of the immunological reaction
The specificity of the Inhibition was studied by using
highly purified preparations of human MM3 and MM1
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Tab. l Recovcry of creatine kinase after incubation of pure MM3
and MM l isoform with monoclonal antibody CKM-G01 (n = 3).
MM3 isoform MM l isoform






























































ficients of x2 did not differ significantly from zero
(p = 0.206 and p = 0.052, respectively)).
Precision
Results of precision studies are shown in table 2. These
studies included estimates of "within-run" and "total"
imprecisions, each determined at normal, above-normal,
and high creatine kinase isoform ratios, using appropri-
ate samples from three patients, selected without con-
scious bias from a hospital population. The method of
estimating imprecision was the analysis of variance
experiment described in the EPS document of the
National Committee for Clinical Laboratory Standards
(25), including two replicates per specimen per run and
one run per day for 20 days. In addition, the analytical
imprecision of total creatine kinase measurement with
the present method was monitored daily with internal
quality-control material consisting of pooled human
serum. The monthly Standard deviation over 4 months
ranged from 4.7 to 6.5 U/l with a mean activity of nearly
100 U/l; the mean Standard deviation was 5.3 U/l, giving
a coefficient of Variation of 5.3%, which compared
favourably with common routine assays for creatine kin-
ase determinatiori.
isoforms. As presented in table l, we found practically
no Inhibition of the antibody with MM l isoform,
whereas CKM-G01 inhibited more than 99% of purified
MM3 isoform.
Investigation of the effect of incubation time on the in-
activation of the MM3 isoform showed that the Inhi-
bition was complete within 3 minutes at 37 °C (data
not shown).
Reagent stability
The wprking, ready to use Solutions were stable for 20
days when refrigerated.
Linearity
Under the conditions described, the assay *was linear for
total and residual creatine kinase activity in serum up
to 1500 U/l. We serially diluted a creatine kinase-rich
specimen with heafc-inactivated serum. Five sep rated di-
lutions were assayed, and each dilution was run three
times. The Standard curves showed no significant curva-
ture, when tested for linearity s suggested by Burnett
(24) (for total creatine kinase activity: quadratic re-
gression, y = -0.46 -l· 404.54x - 9.12x?, and for re-
sidual creatine kinase activity: quadratic regression,
y=-4.42 + 201.18x - 23.03x2, where the coef-
Interference studies
Components of uraemic plasma such s urea, creatinine,
and uric acid do not interfere up to concentrations of 85
mmol/1, 4500 μιηοΐ/l, and 3000 μιηοΐ/ΐ, respectively. We
also found no interference by bilirubin (up to 340
μτηοΐ/ΐ), haemoglobin (up to l g/l), triacylglycerols (up
to 12 mmol/1), glucose (up to 55 mmol/1), or adenylate
kinase (up to 0.5 mg/1).
Method comparison
The results of the analytical comparison between the im-
munoinhibition assay and the immunochemical assay for
Tab. 2 Analytical imprecision of creatine kinase isoform ratio de-





































All runs were performed with a single lot number of reagent kits.
*: creatine kinase isoform ratio was calculated s follows: total
ereatine kinase catalytic eoncentration - residual creatine kinase
catalytic concentration/residual creatine kinase catalytic eoncentra-
tion.
Eur. J. Clin. Chem. Clin, Biochem. / Vol. 32. 1994 / No. 5







600 8000 200 400
Immunochemical assay,
MM1 isoform [U/l]
Fig. l Correlation of results for non-inhibited creatine kinase ac-
tivity by immunoinhibition assay (y-axis) with those for MM l iso-
form by the immunochemical assay (x-axis).
Linear regression analysis yields a regression equation of
y = 1.24x + 14.2 (solid line) with coefficient of correlation of
0.9815 and a Standard error of estimate of 38.4.
The number of patient samples was 39 and total creatine kinase
activities of sera ranged frorn 23 to 4098 U/l.
39 individual random samples submitted to our clinical
laboratory are shown in figure 1. As can be seen, the
results showed a close overall correlation.
Correlation of the creatine kinase isoform ratios deter-
mined by the proposed method (y) with those deter-
mined by Helena's electrophoretic method (χ: ΜΜ3/
MM l isoform ratio) yielded a regression equation of
y = 0.56x + 0.92, with a correlation coefficient of
0.9075 (n = 93). Values for total creatine kinase were
also compared for patient sera assayed by both the pre-
sent method (without CKM-G01 antibody) (y) and the
method recommended by the International Federation of
Clinical Chemistry (χ). The correlation coefficient was
0.9992 and the regression equation was y = 1.03x — 1.7
(n = 91). This good correlation allows the calculation of
the isoform ratio independently of the enzyme assay
used for total creatine kinase determination.
Reference interval
To establish the reference interval of the creatine kinase
isoform ratio, sera were studied from 128 healthy sub-
jects with total creatine kinase activity within the refer-
ence interval for our laboratory (upper reference limit,
160 U/l for women and 190 U/l for men). We then calcu-
lated the reference interval, using non-parametric deter-
mination of percentiles. Reference ranges of the isoform
ratio, defmed s 2.5th-97.5th percentile, were 0.14-
0.79 in females and 0.19-0.95 in males (Wilcoxon rank-
sum test, p = 0.0046), indicating a slight preponderance
of the M(lysine)-monomer in men (flg. 2). An age differ-
ence was not detect ble in the age r nge 20 tp 70 years.
Comparison studies in patients with
myocardial infarction
There is a more rapid and early increase in serurn cre-
atine kinase isoforms after successful coronary reper-
fiision in patients with acute myocardial infarction. We
therefore compared the dhange'in creatine kinase is -
form activities and ratios detemained with both immuno-
inhibition aiid electrophoretic assays over the first h urs
after therapy in patients with and without coronary reca-
naliz tion, verified by independent criteri (figs. 3 and
4). Alsos in this particular clinical Situation the results
from the immunoinhibition assay cprrelated well with
those from the coriventional electrophoretic method.
Figure 5 shows the time-course of the creatine kinase
isoform ratio determined by the immunoinhibition assay,
compared with total creatine kinase activity, myoglobin
and creatine kinase MB concentrations in the same
patients. As can be seen, the time-co f se of the isoform
ratio after thrombolysis was similar to the sharp profile
of myoglobin release into the circulati n, partictilarly in
the reperfused patients.
Since the most promising application of biochemical
markers for the early detection of myocardial reper-
fusion involved examining the rate of increase of the
marker in the blood, we compared the rate of increase
of the creatine kinase isoform ratio with the rates of
increase of total creatine kinase activity and of myoglo-
bin and creatine kinase MB concentrations in the two
groups of patients in the first two hours after throm-
bolytic therapy (tab. 3). The rates of release of total
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Fig. 2 Frequency histograms of the creatine kinase isoform ratio
determined by the immunoirihibition method for the studied refer-
ence population;
(a) mates; (b) females. »»v
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Fig. 3 Time-variable profiles of creatine kinase isoforms (mean
values ± SD) from myocardial infarction patients after thrombo-
lytic therapy (solid line, reperfused; dashed iine, not reperfused).
(a) Creatine kinase tissue isoforms (M(lysine)-monomer inhibited
activity) by immunoinhibition assay;
(b) MM3 isoform and
(c) MB2 isoform activity by electrophoresis.
i l
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Fig. 4 Time-variable profiles of creatine kinase isoform ratios
(mean values ± SD) from myocardial infarction patients after
thrombolytic therapy (solid line, reperfused; dashed line, not reper-
fused).
(a) Creatine kinase isoform ratio by immunoinhibition assay;
(b) MM3/MM1 isoform ratio by electrophoresis and
(c) MB2/MB1 isoform ratio by electrophoresis.
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Fig. 5 Time^variable profiles of
myoglobin (solid square),
total creatine kinase (solid rhombus),
creatine kinase MB (solid triangle) and
creatine kinase isoform ratio by immunoinhibition assay (solid
circle)
from myocardial infarction patients after thrombolytic therapy
(mean values; solid line, reperfused; dashed line, not reperfused).
patients were significantly greater than in non-reper-
fused myocardial infarction patients. On the other band,
although their rates of release were higher in the reper-
fused group, the differences for myoglobin and the iso-
form ratio were not statistically significant, owing to the
small number of patients studied.
Discussion
CKM-G01 was the first monoclonal antibody to be re-
pofted that inhibited the native M subunit of creatine
kinase, but not after removal of lysine from the subunit
by carboxypeptidase (15). Recently, an automatable di-
agnostic test, based oii the immunoinhibition method,
and not requiring Separation of isoforms, was developed
with the use of this antibody (16, 17). Accordingly, the
assay can reliably distinguish tissue M(lysine)-monomer
from circulating monomer with no carboxy-terminal ly-
sine, yielding a derived isoform ratio (inhibited/residual
activity) which could be used for early diagnosis of
myocardial infarction and coronary artery recanalization
(l, 4). Current methods for measuring this ratio (tissue/
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Tab. 3 Rate of increase (mean ± SD) in the blood of myoglobin, total creatine kinase, creatine kinase MB, and creatine kinase isoform
ratio in patients vvith acute myocardial infarction in the first two hours after thrombolytic therapy.
Myoglobin, g/l min
Total creatine kinase, U/l min
Creatine kinase MB, g/l min



















serum isoforms) are generally time-consuming and corn-
plicated. At the present time, creatine kinase isoforms
are not assayed routinely, mainly because of the diffi-
culty in incorporating such a technique into the clinical
laboratory routine, to be used on a 24-hours-per-day, 7-
days-per-week basis, äs demanded by clinicians (10). A
rapid turnaround time for the assay is essential if ad-
ditional interventions are to be implemented on the basis
of the results. Consequently, a simple, reliable, and rapid
analysis for measuring creatine kinase isoforms in serum
is required. We presented evidence for the adequacy of
the immunoinhibition assay, which is nearly äs accurate
äs the electrophoretic procedure, a generally accepted
analytical method whose assay performance is well
documented (1,6). The procedure can be fully mechan-
ized on several types of automated analysers, permitting
creatine kinase isoforms to be measured with a con-
venience approaching that of the total creatine kinase
assay. There is one important shortcoming, namely the
fact that the procedure cannot separate MM and MB
isoforms. Compared with direct creatine kinase MB iso-
form measurement, this assay may be less specific for
the early diagnosis of myocardial infarction (6). Thus,
the test can be more useful for reperfusion studies than
for early diagnosis, because the former are not limited
by the problem of low clinical specificity (a working
diagnosis of infarction has already been established). As
recently confirmed by Adams et al. (26), criteria based
on both the rate of rise and absolute values of creatine
kinase isoforms in plasma may be capable of dis-
tinguishing patients with persistent recanalization from
those with transient reperfusion followed by occlusion.
Conclusion
The use of the proposed assay offers a simple and re-
liable method for quantification of creatine kinase iso-
forms in serum. In particular, the results are obtained
within 10 minutes and can be made available during
nights, Weekends, and holidays in a stat lab. Laboratories
could easily provide clinicians with values for creatine
kinase isoforms in emergency situations for prospective
patient management.
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